The conceptual relevance of assessment measures in patients with mild/mild-moderate Alzheimer\u27s disease by Hartry, Ann et al.
Thomas Jefferson University
Jefferson Digital Commons
College of Population Health Faculty Papers Jefferson College of Population Health
8-10-2018
The conceptual relevance of assessment measures
in patients with mild/mild-moderate Alzheimer's
disease
Ann Hartry
Lundbeck, Deerfield, IL
Natalie V.J. Aldhouse
DRG Abacus
Tamara Al-Zubeidi
DRG Abacus
Myrlene Sanon
Otsuka Pharmaceutical Development & Commercialization, Inc.
Richard G. Stefanacci
Thomas Jefferson University, richard.stefanacci@jefferson.edu
See next page for additional authors
Let us know how access to this document benefits you
Follow this and additional works at: https://jdc.jefferson.edu/healthpolicyfaculty
Part of the Geriatrics Commons, and the Public Health Commons
This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital Commons is a service of Thomas
Jefferson University's Center for Teaching and Learning (CTL). The Commons is a showcase for Jefferson books and journals, peer-reviewed scholarly
publications, unique historical collections from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and
interested readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been accepted for inclusion in
College of Population Health Faculty Papers by an authorized administrator of the Jefferson Digital Commons. For more information, please contact:
JeffersonDigitalCommons@jefferson.edu.
Recommended Citation
Hartry, Ann; Aldhouse, Natalie V.J.; Al-Zubeidi, Tamara; Sanon, Myrlene; Stefanacci, Richard G.;
and Knight, Sarah L., "The conceptual relevance of assessment measures in patients with mild/mild-
moderate Alzheimer's disease" (2018). College of Population Health Faculty Papers. Paper 83.
https://jdc.jefferson.edu/healthpolicyfaculty/83
Authors
Ann Hartry, Natalie V.J. Aldhouse, Tamara Al-Zubeidi, Myrlene Sanon, Richard G. Stefanacci, and Sarah L.
Knight
This article is available at Jefferson Digital Commons: https://jdc.jefferson.edu/healthpolicyfaculty/83
Cognitive & Behavioral Assessment
The conceptual relevance of assessment measures in
patients with mild/mild-moderate Alzheimer’s disease
Ann Hartrya, Natalie V. J. Aldhouseb, Tamara Al-Zubeidic, Myrlene Sanond,
Richard G. Stefanaccie, Sarah L. Knightc,*
aLundbeck, Deerfield, IL, USA
bDRG Abacus, Manchester, UK
cDRG Abacus, Bicester, Oxfordshire, UK
dOtsuka Pharmaceutical Development & Commercialization, Inc. Princeton, NJ, USA
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Abstract Introduction: This study aims to evaluate the conceptual relevance of four measures of disease ac-
tivity in patients with mild/mild-moderate Alzheimer’s disease (AD): (1) the Alzheimer’s Disease
Assessment Scale–Cognitive Subscale; (2) the Alzheimer’s Disease Cooperative Study–Activities
of Daily Living Inventory; (3) the Neuropsychiatry Inventory; and (4) the Dependence Scale.
Methods: Aconceptualmodel depicting patient experience ofmildADwas developed via literature re-
view; conceptswere comparedwith the itemsof the fourmeasures.Relevanceof the concepts included in
the four measures was evaluated by patients with mild AD in a survey and follow-up interviews.
Results: The four measures assessed few of the symptoms/impacts of mild AD identified within the
literature. Measured items addressing emotional impacts were deemed most relevant by participants
but were included in the measures only superficially.
Discussion: The four assessment measures do not appear to capture the concepts most relevant to/
important to patients with mild/mild-moderate AD.
 2018 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).
Keywords: Mild/mild-moderate Alzheimer’s disease; Outcome measures; Patient-reported outcome (PRO); Conceptual rele-
vance; Quantitative survey; Qualitative interviews
1. Introduction
Alzheimer’s disease (AD) is a progressive, fatal neurode-
generative diseasewith no known cure. Although disease eti-
ology is unclear, advancing age is the greatest known risk
factor for disease development [1]; approximately 11% of
the US population aged 65 years has AD, and this in-
creases to nearly 32% in those aged 85 years [2]. It is esti-
mated that.5 million individuals in the United States suffer
from AD, which is the sixth leading cause of death in the
nation [1]; prevalence of AD is increasing with aging popu-
lations in the Western Hemisphere, placing an ever-
increasing burden on health-care systems [3].
Recent scientific advances in AD mean that the disease
can now be thought of as a continuum, with both preclin-
ical (asymptomatic but with evidence of AD pathology)
and clinical (symptomatic) phases [4]. The clinical phase
is normally associated with signs and symptoms associated
with a decline in cognitive and functional abilities [5].
Such symptoms are distinguishable from typical age-
related changes [6] and vary greatly depending on where
Declaration of interest: S.L.K., N.V.J.A., and T.A.-Z. are all employees
of DRG Abacus. A.H. is an employee of Lundbeck US, and M.S. is an
employee of Otsuka Pharmaceutical Development & Commercialization,
Inc. DRG Abacus is a health outcomes agency that consults with various
pharmaceutical companies. Lundbeck and Otsuka are both pharmaceutical
companies working to develop new products through research.
*Corresponding author. Tel.: 144 (0)1869 356683; Fax: 144 (0)
1869 220152.
E-mail address: sknight@teamdrg.com
https://doi.org/10.1016/j.dadm.2018.07.006
2352-8729/ 2018 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 10 (2018) 498-508
patients are on the disease continuum. These symptoms can
include the following: (1) memory loss that disrupts daily
life; (2) poor judgment and decision-making; (3) difficulty
having conversations; (4) misplacing items and being un-
able to find them; and (5) changes in mood and personality
[5]. Individuals may present with one or more of these
symptoms, with varying severity, which can have a huge
impact on patients’ and caregivers’ health-related quality
of life [3]. The Food and Drug Administration acknowl-
edges these different stages of AD and that clinical end-
points and associated outcomes will differ for clinical
trials, depending on where patients are on the disease con-
tinuum [7]. Importantly, more subtle changes observed in
the earlier stages of AD may not be as obvious as the
symptoms experienced further along the spectrum. The
focus of this study was on patients who are within the early
clinical phase of AD (mild-moderate).
There are a number of assessment measures used to
assess disease severity in patients with AD; however, the
sensitivity and suitability of some of these in mild-
moderate AD may be limited [2,8,9]. Four measures
commonly used in clinical trials, but rarely used in clinical
practice, are the Alzheimer’s Disease Assessment Scale–
Cognitive Subscale (ADAS-Cog) [10], the Alzheimer’s
Disease Cooperative Study–Activities of Daily Living In-
ventory (ADCS-ADL) [11], the Neuropsychiatry Inventory
(NPI) [12], and the Dependence Scale (DS) [13]. These mea-
sures are summarized in Table 1.
The ADAS-Cog is a composite measure administered by
clinicians, consisting of a clinician-reported assessment
measure and a performance assessment measure [10]. The
measure consists of four domains, which include memory,
language, praxis, and orientation. Variations of the ADAS-
Cog exist, each designed to be more sensitive to a different
stage of disease. The version used here is the 11-item version
designed for mild-to-moderate AD.
The ADCS-ADL is an observer-reported assessment
measure typically administered by caregivers [11]. This
23-item measure is designed to evaluate patient’s daily
living and covers three domains, namely, physical func-
tioning, mental functioning, and independence in self-care.
The NPI is an observer-reported measure used to deter-
mine the presence of psychopathology in patients with
AD/other dementias [12]. There are 12 items subdivided
into a behavioral domain (10 items) and a neurovegetative
domain (2 items). The NPI is based on responses from a
caregiver and assesses the frequency, severity, and distress
experienced for each item.
The DS is a 13-item observer-reported measure adapted
from a scale originally developed to assess dependency in
community-dwelling older people [13]. The DS assesses pa-
tient level of dependency for various daily living activities
(e.g., getting dressed).
Although these assessment measures are commonly used
with patients who have mild/mild-moderate AD, there is lit-
tle evidence to show they capture concepts deemed impor-
tant to these patients [14]. This is compounded by the fact
that none of the measures are patient reported. Although pa-
tients may have some decreased insight due to their disease,
their opinions are important (in addition to clinicians/care-
givers) to ensure that relevant concepts are being measured.
Therefore, the aim of this study is to evaluate the conceptual
relevance of the four outlined assessment measures in the
assessment of mild/mild-moderate AD from the patient
perspective. The results could help determine the suitability
of using these measures in clinical trials involving patients
with mild/mild-moderate AD.
2. Methods
2.1. Steering committee
The researchers worked with the Alzheimer’s Associa-
tion to assemble a steering committee to enhance the patient
centricity and clinical relevance of the research. The com-
mittee comprised a patient representative with mild AD,
an informal caregiver of a patient with mild AD, an advocate
from the Alzheimer’s Association, and a clinical expert with
Table 1
Summary of assessment measures used to assess disease activity in patients with AD
Properties
Assessment measure
ADAS-cog ADCS-ADL NPI DS
Aspect of disease activity
evaluated
Cognitive impairment Activities of daily living Presence of psychopathology Level of dependency
(for daily living
activities)
Type of assessment measure Composite (clinician-reported
and performance)
Observer-reported Observer-reported Observer-reported
Number of items 11 23 12 13
Administered by Clinician Caregiver Caregiver Someone who lives with
patient
Recall/evaluation period None Previous 4 weeks Typically 4 weeks of observation N/S
Abbreviations: ADAS-Cog, Alzheimer’s Disease Assessment Scale–Cognitive Subscale; ADCS-ADL, Alzheimer’s Disease Cooperative Study–Activities of
Daily Living Inventory; DS, Dependence Scale; NPI, Neuropsychiatry Inventory; N/S, not stated.
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experience in memory problems and AD. The patient repre-
sentative and informal caregiver were recruited through dis-
cussion with the Alzheimer’s Association, who suggested
suitable members after a full description of study require-
ments. The clinical expert was recruited based on their
expertise with managing patients with AD (minimum of
10 years) and on their experience with outcomes research
in this area.
2.2. Assessment of conceptual coverage
2.2.1. Development of a conceptual model for mild AD
A targeted electronic literature review was conducted to
identify qualitative publications reporting the patient experi-
ence of mild AD. A detailed search strategy combining
search terms for AD and qualitative research was developed
to identify all relevant publications, (presented in full in the
Supplementary Information [Table 5]). Titles and abstracts
of publications from the searches were screened using spe-
cific inclusion criteria (Table 2). Studies with English-
speaking populations and clear definitions of mild AD
were included. Included studies were reviewed to extract
relevant concepts using qualitative methods facilitated by
ATLAS.ti, version 7, software. A conceptual model (CM)
of the patient experience of mild AD was subsequently
developed to illustrate the relationship(s) between the iden-
tified concepts. Concepts (things that were identified as be-
ing important) were distinguished as either a symptom
(e.g., memory loss) or an impact (e.g., difficulty driving)
and grouped into domains of related experiences. The model
was reviewed, modified, and approved by the steering com-
mittee.
2.2.2. Analysis
Items from the four assessment measures were compared
with the concepts identified from the qualitative literature re-
view. Compatibility between the CM and assessment mea-
sures was evaluated to determine whether the measures
included concepts considered important to patients, and
whether any irrelevant concepts were included or not
included.
2.3. Assessment of relevance
2.3.1. Patient survey
2.3.1.1. Survey design
A quantitative survey was designed to capture data on
patient-reported disease severity and symptom botheration.
Survey content was predominantly based on the most rele-
vant concepts extracted from the four assessment measures,
with additional concepts deemed to be of significant impor-
tance added by the steering committee. Survey development
was an iterative process with several review stages and revi-
sions involving the steering committee. Ethics approval was
provided by the New England Independent Review Board
for the study in December 2016 (#120161008).
The survey comprised 11 main questions that asked pre-
dominantly about their AD symptoms and medication. One
of the survey questions asked patients to score a list of “both-
ersome” symptoms (n5 41) on a severity scale ranging from
1 to 5, where 1 was equal to “this does not bother me at all”
and 5 was equal to “this bothers me greatly”. Concepts that
patients had not experienced could be given a score of 0. In
another question, patients were asked how important it is for
them to be able to carry out a number of activities and to
grade their perceived severity of their AD symptoms overall.
There was a 7-day recall period for questions related to both-
ersome symptoms and most important activities. See
Supplementary Information for the full survey.
2.3.1.2. Participant selection
One hundred participants were recruited across five clin-
ical sites at three geographical locations in the United States.
Patients aged 65 years on the day of survey completion
with mild/mild-moderate AD (either confirmed via magnetic
resonance imaging scan or suspected via clinical observation
and/or measurement) were eligible to participate in the sur-
vey. A Mini–Mental State Examination was not
Table 2
Eligibility criteria for study inclusion in the qualitative literature review
Criteria Include Exclude
Population  Patient population aged 50 years
 Patient population with mild AD
 Patient population aged ,50 years
 Patient population with early onset AD only
 Patient population with severe AD as defined within
the specific study
Setting  Patients from English-speaking countries (initial focus
on US data)
 Patients from non–English-speaking countries
Study design  Any study designs which report qualitative patient (or
caregiver reported) experiences (including interviews,
focus groups, and survey designs)
 Studies reporting on concepts relating to symptoms of
mild AD and related impact
 Nonqualitative studies
Publication language  English language  Non-English language
Year of publication  2000–Present (date of search: April 29, 2016)  Before 2000
Abbreviation: AD, Alzheimer’s disease.
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administered/required as part of screening; however, if a pa-
tient had completed it in the past, a score of 18–25 was
required. Participants required an understanding of their
condition and sufficient cognitive, reading, and linguistic ca-
pabilities to complete a five-page pen-and-paper survey in
American English, as determined by their clinician. Partici-
pants had to provide informed consent before study admis-
sion. Individuals were excluded if they were aged
,65 years; had a significant psychiatric/physical comorbid
condition that would prevent study participation (clinician
determined); had a diagnosis of early onset AD; or had a
diagnosis/symptoms suggestive of moderate/severe AD.
Patients completed the survey independently around
March to April 2017 at their physician’s clinical site. A re-
view of the captured data was carried out to check for any
abnormalities after the first five participants had completed
the survey. The remaining 95 participants completed the sur-
vey once no data collection issues were identified.
2.3.1.3. Analysis
Results were analyzed using descriptive statistics in Mi-
crosoft Excel according to a statistical analysis plan
approved before survey implementation.
2.3.2. Patient interviews
2.3.2.1. Interview design
A semistructured patient interview guide was developed
to follow up on questions asked in the survey to obtain addi-
tional information; all patients were asked the same core set
of questions, which aimed to explore patients’ feelings about
their condition and to better understand their survey answers,
e.g., “In the last 7 days, are there any activities or tasks that
you have had trouble with that have bothered you?” As with
the survey, interview guide development was an iterative
process involving the steering committee; questions were
developed through discussion among the team. Ethics
approval was provided by the New England Independent Re-
view Board in March 2017.
2.3.2.2. Participant selection
Fifteen interview participants were recruited from
the group of individuals successfully completing the
quantitative survey, thus eligibility criteria remained the
same. However, patients were only asked to participate if
they completed the surveywith ease.Where possible, a range
of patients with different demographics were recruited.
One-to-one phone interviews were conducted using the
approved interview guide. Interviews were to last approxi-
mately 1 hour and took place between March and May
2017. All interviews were audio recorded with patient con-
sent and transcribed verbatim.
2.3.2.3. Analysis
Transcripts were analyzed, according to the approved
study protocol, using qualitative methods facilitated by AT-
LAS.ti, version 7, software [15]; transcripts were uploaded,
and quotes from the interviews were sorted by domain using
thematic analysis techniques to determine aspects of mild-
moderate AD which were important to patients [16].
Results from the survey/interviews were compared
against the concepts included in the assessment measures
to determine whether the symptoms/impacts of mild-
moderate AD reported as bothersome by patients were
indeed measured.
3. Results
3.1. Assessment of conceptual coverage
3.1.1. Conceptual model of mild AD
The literature review identified 18 articles (17 unique
studies) that were relevant to the target patient population
(Fig. 1).After qualitative analysis, 45 conceptswere identified
which described the patient experience of mild AD,
comprising six symptoms experienced directly due to the dis-
ease (e.g., short-term memory loss) and 39 impacts experi-
enced because of a disease-related symptom. Impacts were
divided into five groups of related experiences (impact on
thought processing, impact on daily activities, impact on
communication, impact on social life, and emotional impact).
An additional four impacts, not identified from the literature
review, were proposed by the steering committee as being
relevant to the patient population. These four concepts, in
addition to those identified during the literature review, were
combined into a CM (Fig. 2). The CM displays each concept
as a visual representation of patients’ symptom experience of
mild AD and aims to show any potential relationships.
3.1.2. Conceptual relevance of assessment measures
The concepts detailed in the CMwere mapped to items in
the four assessment measures (for compatibility).
The ADAS-Cog covered only two of the six symptoms
identified in the CM (short-term memory loss and reduced
cognition) and a limited number of impacts, mostly associ-
ated with communication. None of the other impact domains
(e.g., impact on daily activities and emotional impact) were
covered.
The ADCS-ADL covered most domains and concepts
identified in the model, including “memory loss” and
“reduced concentration” symptoms. However, three symp-
toms (apathy/lack of energy, reduced cognition, and confu-
sion) were not covered. Impacts associated with thought
processing, communication, and daily activities were well
covered by the measure (albeit from a caregiver perspec-
tive). Emotional impact was not covered.
Out of the measures assessed, the NPI covered the fewest
domains and concepts identified by the CM. Only one symp-
tom (apathy) and one emotional impact (depression/suicide
ideation) were covered, although it was the only measure to
cover any of the emotional impacts.
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In terms of overall conceptual coverage, the DS was the
only measure that did not include an assessment of identified
symptoms. Impacts considered important to patients, espe-
cially those associated with daily activities, thought process-
ing, and social life, were covered, but no items covered
emotional impacts. The DS contained several items not iden-
tified by the CM, including incontinence- and feeding-
related impacts.
Twenty concepts identified in the CM were not included
in any of the assessment measures (Supplementary
Information, Appendix A–Table 6). Two symptoms not as-
sessed by any measure were “reduced energy” and “confu-
sion”. Impacts that were not included were generally
emotional rather than physical, including feelings of frustra-
tion, anger, and guilt.
3.2. Assessment of relevance
3.2.1. Patient demographics and clinical characteristics
Clinical and demographic characteristics for the 100 sur-
vey participants are presented in Table 3. Patients’ ages
No. records identified through database search: N=761
Embase, n=228;
Medline, n=157;
PsycINFO, n=376.
No. records screened (by title and abstract): N=579
No. full-text articles assessed for eligibility: N=104
Duplicates: N=182
Exclusion 1st pass: N=475
• Not patient experience, n=378;
• Not Alzheimer’s disease, n=55;
• Population not English-speaking, 
n=21;
• Conference abstract only, n=13;
• Early onset Alzheimer’s, n=3;
• Severe Alzheimer’s, n=3;
• Review paper, n=1;
• Non-English Language, n=1
Exclusion 2nd pass: N=92
• Population not English-speaking, 
n=19;
• Not patient experience, n=14;
• Cause of dementia not reported, 
n=12;
• Severe Alzheimer’s, n=10;
• Mixed severity Alzheimer’s, n=10;
• Mixed causes of dementia, n=6;
• Interventional study, n=4;
• Methodology paper only, n=4;
• Stage of Alzheimer’s not reported, 
n=4;
• Not Alzheimer’s disease, n=3;
• Quantitative analyses only, n=2;
• Moderate Alzheimer’s, n=1;
• Mixed language population, n=1;
• Concomitant neurological 
diagnoses, n=1;
• Early onset Alzheimer’s, n=1.
Included publications, N=18
Identified via hand-searching: N=6
• Reference lists of included studies, 
n=5;
• Reference lists of relevant reviews, 
n=1.
Fig. 1. Preferred reporting items for systematic reviews and meta-analyses (PRISMA) flow diagram for the qualitative literature review. Abbreviation: No.,
number.
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ranged from 65–96 years, (mean age of 77 years), were
mostly Caucasian/White (71%) with some being Black/
African-American (21%), and were mostly retired (81%)
with the majority living with others including their partner
or family (73%).
AD symptoms had been experienced for varying lengths
of time, from less than six months (7%) to over ten years
(10%)withmost having experienced symptoms for 1–2 years
(38%). Most participants had received a diagnosis of mild
AD (83%), a much smaller number had a diagnosis of
mild-moderate or moderate disease (4%; 68%), which had
been diagnosed using the Mini–Mental State Examination.
Just under half the patients surveyed (46%) were
receiving medication to treat the symptoms of AD (mean
duration on current medication of 25 months) (Table 3).
3.2.2. Survey and interview results
Patients were able to report their symptom severity and
AD disease experience via the survey and, if suitable,
through a subsequent interview, which provided patients
with the opportunity to further discuss their feelings.
Each assessment measure concept was endorsed as expe-
rienced and bothersome by at least one patient. The ten most
commonly experienced concepts are outlined in Table 4.
“Worrying about my disease getting worse,” a concept
included by the steering committee and not included in any
of the assessment measures, was identified as the most bother-
some impact from both the survey (reported as the most both-
ersome impact by 23% patients) and interview and was
experienced by 73% of survey participants. “Loss of identity”,
also addedby the steeringcommittee; “remembering the names
of people and common objects”, assessed by the DS, ADCS-
ADL, and ADAS-cog; and “not being able to find familiar ob-
jects” assessedby theDSandADCS-ADLwere also among the
most bothersome impacts experienced (experienced by 41%,
82%, and 78% of survey participants, respectively).
Patients were also asked to provide any additional
symptoms and impacts that they found bothersome because
of AD. Six participants described difficulty driving or get-
ting lost while navigating, three described not being fully
independent and their need to rely on others, and two
mentioned poor organizational skills—these were concepts
Memory loss
Long-term Short-term
Reduced 
concentration
Reduced 
cognition
Confusion
Apathy, lack of 
energy
Emotional impact
Frustration, anger
At symptoms/ 
impacts
At reliance on 
carer
Guilt
At symptoms/ 
impacts
At reliance on 
carer
Worry about 
getting worse
Depression, 
suicide ideation
Lowered 
confidence
Humiliation
Changed roles, 
lost authority
Impact on daily activities
Difficulty 
completing tasks
Difficulty keeping 
appointments
Difficulty driving Increased resting, sleeping
Unable to manage 
health and medications
Impact on chores
Difficulty 
cooking
Difficulty doing 
housework
Difficulty doing 
finances
Difficulty doing 
handy-work, DIY
Difficulty walking 
pets
Impact on thought processing
Wandering, 
getting lost Disorientated
Leaving things 
in odd places
Forgetting 
where things are
Difficulty making 
decisions
Poor time-
keeping
Forget have AD Need for routine, system
Dependent on 
memory aids
Dependent on 
carer
Impact on social life
Impact on 
hobbies
Forgetting 
names
Forgetting 
visitors
Impact on communication
Word-finding 
difficulties
Repetitive 
question-asking
Unable to make 
sense
Unable to follow 
conversation
Symptoms
Impacts on daily life
Emotional impacts
Symptoms fluctuate, “Good days and bad days”
Fear of social 
isolation
Loss of identity
Additional concepts identified 
by steering committee
Loss of 
autonomy 
Fig. 2. Conceptual model visually representing the concepts identified by the literature review and steering committee as being most relevant to patients with
mild AD.
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identified by the qualitative literature review and included
in the CM.
Patients rated most activities as being important to do to
remain independent. Consequently, it was difficult to deter-
mine which single activity was most important to patients;
however, “the ability to maintain my health and safety”
was reported by the highest number of participants (12%)
and yet was not represented by any of the measures. Of
the activities not captured within the survey, driving was re-
ported as being important to maintain independence (n5 4).
This was corroborated by the interviews, with several pa-
tients reporting how important driving was to them.
Overall, survey results appeared to reflect those that were
raised in the interviews, that is, the most bothersome symp-
toms and impacts reported in the survey were also reported
in the interviews. However, there were some discrepancies
between individuals’ responses to the survey questions and
answers given in the interview, mainly in relation to self-
reported symptom severity where 11 patients answered
differently in the survey compared with the interview.
Although not a concept or an impact, it is interesting to
note and could suggest disease fluctuation. A number of psy-
chological and emotional impacts were reported by patients
in greater detail during the interviews; nearly all patients re-
ported one or more bothering feelings including depression,
demotivation, frustration, embarrassment, anxiety, and fear.
4. Discussion
This study provides an overview of the conceptual rele-
vance of four assessment measures assessing patients with
mild/mild-moderate AD from the patient perspective. The
results suggest that the most important symptoms to these
patients are related to memory and communication, and
the most important impacts are more emotional and psycho-
logical than physical. Fear of deterioration (“worrying about
my disease getting worse”) was highlighted as being a very
important and relevant concept which was not reflected in
the reviewed measures. Similarly, “loss of identity” was
flagged as a recurrent patient concern also missing from
the measures. In addition, patients were concerned about
their ability to carry out activities of daily living in relation
to remaining independent, such as driving. As seen in the
concept matrix (Supplementary Information, Table 6),
some of the included assessment measures do include these
high-level symptom concepts (e.g., the ADAS-Cog includes
an item to capture memory loss). However, it can also be
seen that not all of the symptoms or memory issues identified
as being important or relevant to patients are captured (e.g.,
reduced concentration), nor are they patient reported. Issues
associated with emotional and psychological impacts were
generally poorly covered by the four clinical assessment
measures. This could be because emotional concepts are
difficult to collect from clinician- or observer-reported mea-
sures and are better collected from patients themselves.
These existing clinical measures may also not be granular
enough to detect subtle changes that occur at mild/mild-
moderate disease stages and may be better suited for evalu-
ating individuals with severe AD because they capture
impact on basic activities (e.g., toileting independently). Ac-
tivities requiring a higher level of cognition and ability were
considered more important to patients with mild/mild-
moderate AD for them to remain independent and are con-
cepts not covered by the measures.
Symptoms reported during interviews and in the survey
were in good levels of agreement with one another. The vari-
ation noted between the symptom severity score given dur-
ing the survey and interviews by individual patients could
be attributed to variability in symptoms of AD over time.
The current research does appear to demonstrate that pa-
tients with mild/mild-moderate AD are capable of reporting
Table 3
Demographics and clinical characteristics of survey and interview
participants
Characteristic
Survey
participants,
N 5 100 (%)
Interview
participants,
N 5 15 (%)
Age (years)
Mean (SD) [range] 77 (67) [65–96] 76 [66–88]
Gender
Male 49 (49) 7 (47)
Female 50 (50) 8 (53)
Prefer not to say 1 (1) 0
Ethnicity
Caucasian/White 71 (71) 11 (73)
Black/African American 21 (21) 3 (20)
Other/Mixed/Multiethnic 4 (4) 1 (7)
Hawaiian/Pacific Islander 3 (3) 0
Hispanic 1 (1) 0
Living situation
Living with spouse/partner 58 (58) 9 (60)
Living alone 26 (26) 3 (20)
Living with family 15 (15) 3 (20)
Living in sheltered accommodation 1 (1) 0
Time since symptom onset
,6 months 7 (7) 2 (13)
6 months–1 year 14 (14) 4 (27)
1–2 years 38 (38) 3 (20)
3–4 years 18 (18) 3 (20)
5–10 years 8 (8) 3 (20)
.10 years 10 (10) 0
Unknown 5 (5) 0
Age at diagnosis
Known 72 (72) 10 (67)
Mean age in years (SD) [range] 75 (67) [63–94] 74 [66–86]
Unknown 17 (17) 2 (13)
Suspected—no yet confirmed 11 (11) 3 (20)
Medication usage
Currently receiving medication 46 (46) 7 (47)
Mean months on
medication (SD) [range]
25 (630) [0–153] 38 [3–98]
Not currently receiving medication 54 (54) 8 (53)
Of which, previously received
medication
3 (6) 1 (13)
Abbreviation: SD, standard deviation.
A. Hartry et al. / Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 10 (2018) 498-508504
Table 4
Ten most common concepts (symptoms or problems) experienced by survey participants and relevant quotes extracted from interviews
Concept
Survey participants
experiencing and bothered
by symptom, N 5 100 Associated quotes from patient interviews
Remembering a list of items 85%  “Right before I go to get my groceries I usually try to write a few words, but
invariably I have forgotten some other things. I: The ones that you have
written down do you mainly remember to get them? Yes, I manage to get them
after hunting through the grocery shopping. The people are not very helpful,
they say you’ve just got to look around and look around to find these things,
and then I try to remember them but it’s hopeless for me, don’t know which
row is it, was row four or row five looking for food, and I can’t think of the
numbers. I always say to myself I’ll remember that is row four, then I go to row
four but I have forgotten what the hell I want.” (02–31)
Remembering names of
people and common objects
82%  “I have like my next door neighbor he will come up and I will say oh man
what’s his name? I forgot his name, and I do that a lot, and so forth.” (02–50)
 “People that I know their face and I haven’t seen them in a long time and I
can’t think of the name, and they will come to me and they say, “Hi [name],
they remember my name and I don’t remember theirs.” [Laughs] so that’s a
concern, especially if I’m at a place like we had a reunion or something like
that, and these people I haven’t seen in years.” (02–34)
 “I’m forgetting names and my wife has to help me.” (01–05)
Misplacing things 80%  “I couldn’t remember where I had put things, and I couldn’t find them, and
that’s not me.” (05–93)
Not being able to find
familiar objects
78%  “Well it bothers me because I can’t find it, the key to my car and don’t have no
idea what happened to it.” (02–29)
Worrying about my
disease getting worse
73%  “.it makes you wonder about your independence, howmuch will you be able
to do. You really don’t want to have to count on anybody else, even though you
know they would be there, but it’s like I don’t want to ask people to take me to
my doctor’s appointments, or to cook me lunch or dinner, I don’t want to have
to ask people to do those things.” (01–19)
 “See, if I feel like getting up in the morning, I get up. If I don’t feel like getting
up, I don’t have to get up you see and the way that I live my life well then if I
was dependent on other people it would be different. So, that bothers me too
because I have my own routine I like.” (02–29)
 “.Well I’m not an angry person, I never really get angry that much, I’m very
easy-going but I don’t know if my personality will change or not.” (04–71)
 “Well, it’s a little bit scary knowing that right now I’m considered more mild
but down the road I don’t know what’s going to happen and it’s scary.” (04–
71)
Expressing myself verbally, that is,
finding the right words and
being understood
71%  “I guess that makes my conversations very short because if I go on a long time
I will lose the concentration.” (02–29)
 “It’s just well really when I’m talking to people.I could be going and all of a
sudden I would be talking to them and all of a sudden boom I just go just I
forget what I was talking about.” (02–50)
 “.that concerns me when I’m talking about something, and there’s a word
that I want to use to describe something and I can’t think of the words.” (02–
34)
 “It’s like I want to say something and then I can’t remember, and then I get
aggravated, and then it’s like I jumble my words in, because it’s just.
doesn’t come out like I would like it to be.” (03–53)
 “I don’t know how to word it but sometimes I do get aggravated with myself,
because I can be talking to her and then just she’ll be doing something else
and then I forget what I was talking to her about or something, once in a
while.” (03–52)
Confusion regarding date and time 70%  “Just being able to know what clothes will go together and what the time of
the year is, and things like that, so that you know just the basic things.” (01–
19)
Change in mood (e.g., being easily
irritated in a way that I was
not previously)
69%  “.there’s a lot of things like working around trying to fix things and
everything, and I think I could do it and everything, and then I go and do it
and then I mess up with it, and I get all messed, worse than what it was. So I
get all frustrated over that, and besides other things. I get all frustrated up.”
(02–50)
(Continued )
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important issues that affect them and also like to be involved
in research.
From the combined results of this research, it can be
concluded that the ADAS-Cog, ADCS-ADL, NPI, and DS,
all regularly used in clinical trials, do not appear to capture
the full breadth of concerns of patients with mild/mild-
moderate AD. Ensuring measurement of the concepts that
are identified as those that matter to patients may help to
distinguish whether new treatments are successful within a
trial (as they will be assessing change on concepts that are
relevant to patients). Published literature also suggests that
these commonly used outcome measures may not be the
most suitable to identify reliable change in patients with
early AD [9,17]. A number of high-level concepts assessed
by these measures are relevant to patients. A larger number
of concepts deemed of greatest importance to patients
(including activities such as driving) are not included, nor
are they captured directly from the patient. Indeed, pub-
lished literature also suggests that although commonly
used, historical measures, including the ADAS-Cog and
NPI, may be less suitable for use in patients with milder
AD because of the discrepancy between presenting symp-
toms and those included in the assessments [18,19].
Thought should therefore be given to what matters most
to these patients before selecting suitable endpoints for clin-
ical trials and, therefore, suitable assessment measures to
capture these. Patient and clinician interviews should be
conducted before clinical trial endpoint selection. In addi-
tion, a full review should be undertaken to identify whether
an existing measure can be used (or a composite created) or
whether a new patient-reported outcome measure needs to
be developed for use in clinical trials of mild AD patients.
4.1. Limitations
Although the overall study was designed appropriately
and implemented according to protocol, several limitations
are acknowledged. Only studies reporting in English-
speaking populations with defined mild AD were included
in the literature review. Consequently, relevant studies re-
ported in other languages or with less well-defined descrip-
tions of mild AD may have been excluded. Despite this, the
stringent inclusion criteria ensured that all included concepts
were highly relevant to the target population.
The inclusion of mixed methodology (quantitative and
qualitative) within the study aimed to obtain substantial
breadth and depth of data from patients. However, not all
concepts identified by the literature review, steering commit-
tee, and assessment measures could be included in the sur-
vey because of length restrictions. This was mitigated by
only including the concepts approved as most relevant by
the steering committee and providing patients with an
Table 4
Ten most common concepts (symptoms or problems) experienced by survey participants and relevant quotes extracted from interviews (Continued )
Concept
Survey participants
experiencing and bothered
by symptom, N 5 100 Associated quotes from patient interviews
Feeling down or depressed
(e.g., feeling sad or tearful)
65%  “Well sometimes I do get a little depressed because well. I never experi-
enced this before so I do get a little depressed at times and then at times I’m
fine.” (04–71)
 “So I just I don’t really hardly ever say I got bad days, I just may have I call it
a little depression sometimes, whatever.” (03–52)
 “.I can see where there’s a bigger problem, the depression is, I don’t know
whether I’ve gone on depression one has to have to be hospitalized for de-
pression.I: And you feel that the depression goes very closely with the
memory problems? They sort of go hand in hand? I really do, I really do.”
(01–05)
 “Sometimes I get depressed because it’s just I think it’s like anything, it’s like
the process of getting older and you know that things are slipping, they’re not
the way they used to be when they were say in your 30s or 40s. Your life isn’t
exactly the same anymore. I: I understand that, and so how often do you feel
down would you say? Probably at least once a week. It impacts me by I
don’t want to do anything, I don’t want to see anybody, I don’t want to talk to
anybody, I want to sit and just vegetate, just put everything out of mymind that
I can.” (01–19)
 “I’m tired and then I have no ambition, I think I just don’t feel like. dusting
and vacuuming and things like I used to.” (03–51)
Following instructions 65%  “Well like cooking, the food isn’t the same as it used to be when I used to
remember what I was doing with each ingredient, like I will make a recipe
now, because I have always cooked out of my head, and then I will say why
does it taste different? Because I forgot to put this in there. Like one of my
grandkids will tell me, “Grandma you forgot to put the mustard in there,” or
you forgot to put whatever.” (01–19)
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opportunity to discuss symptoms that may have not been
included in the survey in the follow-up interviews.
For the interviews, participants were selected if they had
completed the survey with ease and if they were deemed
“able” enough to complete the interview. This selection pro-
cess meant that it was more likely that patients with milder
AD with the lowest disease activity were chosen for inter-
view. Consequently, the full range of disease experience
may not have been represented. Another point to note, as
with all qualitative data capture, is that patients may have
answered in a way that made their responses socially desir-
able. This was mitigated by cross-checking responses
(where possible) with the quantitative survey results.
No primary data were collected from caregivers or indi-
viduals living with the patient who could potentially provide
additional insight into the daily problems of the patient. This
suggestion was put forward by steering committee and
should be considered for future studies.
5. Conclusion
The four assessment measures reviewed in this study do
not appear to capture many of the concepts reported as being
most important to patients with mild/mild-moderate AD (i.e.,
emotional and psychological impacts) instead of focusing on
physical ability and symptoms. Patient-reported assessment
measures may be more suitable for assessing function and
ability in patients with mild/mild-moderate AD than clinician
or observer reports made in isolation and should therefore be
considered for use alongside these reports, providing addi-
tional context and understanding. These findings should be
considered in clinical trial research involving patients with
mild/mild-moderate AD and reporting health-related out-
comes with a focus on eliciting what matters most to patients.
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RESEARCH IN CONTEXT
1. Systematic review: The authors reviewed qualitative
literature using traditional sources to develop a con-
ceptual model of mild Alzheimer’s disease (AD).
The authors were aware of the four assessment mea-
sures used in clinical trials of mild AD patients and
included in this study. It was hypothesized that there
may be discordance between concepts that these
measures assess and concepts identified as important
by patients with mild AD.
2. Interpretation: Findings from the research (literature,
quantitative patient survey, and qualitative inter-
views) confirmed that patients identified additional
concepts as being most important compared with
those captured in the measures (low conceptual rele-
vance).
3. Future directions: The manuscript proposes that
emotional and psychological impacts associated
with mild AD are of greatest importance to patients.
Some existing measures such as those included in
this study do not assess these and therefore may not
be able to detect more subtle changes in a clinical
trial situation.
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